Home  >  Research  >  Labs  >  Cancer Program  >  CANCER EPIGENETICS


Beltran A.S., Graves, L.M., Blancafort, P. Novel role of Engrailed 1 as pro-survival factor in basal-like breast cancer and engineering of interference peptides to block its oncogenic function. Oncogene. 2013 Oct 21. doi:10.1038/onc.2013.422. [NCBI PubMed Entry]

Prabhakaran, P., Hassiotou, F., Blancafort, P., Filgueira, L. Cisplatin induces differentiation of breast cancer cells. Front Oncol. (2013) Jun 3;3:134. doi: 10.3389/fonc.2013.00134. [NCBI PubMed Entry].

Hassioutou, F. Hepworth, A. Beltran, AS. Mathews, M. Stuebe, A. Hartmann, P. Filgueira, L. and Blancafort, P. Expression of the pluripotency transcription factor OCT4 in the normal and aberrant mammary gland. Front Oncol. (2013) Apr 11;3:79. doi:10.3389/fonc.2013. [NCBI PubMed Entry]

Van der Gun BTF, Huisman C., Stolzenburg S., Kazemier HG, Ruiters, MHJ., Blancafort, P. Rots MG (2013), Bidirectional modulation of endogenous EpCAM expression to unravel its function in ovarian cancer.BJC. In Press. [NCBI PubMed Entry]

Juárez-Moreno K, Erices R, Beltran AS, Stolzenburg S, Cuello-Fredes M, Owen, GI, Qian H, Blancafort P (2013). Breaking through an epigenetic wall: Re-activation of OCT4 by KRAB-containing designer zinc finger transcription factors. Epigenetics. Jan 11;8(2). [Epub ahead of print]PMID: 23314702 [NCBI PubMed Entry]

Wang Y, Su H-h, Yang Y, Zhang L, Blancafort P, Huang L. Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. Molecular Therapy. (2012); Dec 11. doi: 10.1038/mt.2012.250. [NCBI PubMed Entry]

Blancafort P, Jin J, Frye S (2012). Writing and re-writing the epigenetic code of cancer cells: from engineered proteins to small molecules. Mol Pharmacology Minireview. Available on line http://molpharm.aspetjournals.org [NCBI PubMed Entry]

Hassiotou F, Beltran A, Chetwynd E, Stuebe AM, Twigger AJ, Metzger P, Trengove N, Tat Lai C, Filgueira L, Blancafort P, Hartmann PE. Breastmilk is a Novel Source of Stem Cells with Multi-Lineage Differentiation Potential. Stem Cells. (2012) Aug 3. doi: 10.1002/stem.1188. [NCBI PubMed Entry]

Stolzenburg S, Rots MG, Beltran AS, Rivenbark AS, Yuan X, Strahl BS, Blancafort P (2012) Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research. (2012); 40:6725-40. [NCBI PubMed Entry] Significance: This paper was selected for the Highlights of the Journal (and the cover), which comprises 5% of the papers based on innovation and scientific excellence.

Lara H, Wang Y, Beltran AS, Juarez-Moreno K, Yuan X, Kato S, Leisewitz AV, Cuello-Fredes M, Licea AF, Connolly DC, Huang L, Blancafort P. Targeting serous epithelial ovarian cancer with designer zinc finger transcription factors. J Biol Chem. (2012); 287:29873-86. [NCBI PubMed Entry]

Rivenbark AG, Beltran AS, Yuan X, Rots MG, Strahl BD, Blancafort P. Epigenetic Reprogramming of Cancer Cells via Targeted DNA Methylation. Epigenetics (2012); 7:350-60. [NCBI PubMed Entry]

Huang X, Narayanaswamy R, Fenn K, Szpakowski S, Sasaki C, Costa J, Blancafort P, Lizardi PM. Sequence-Specific Biosensors Report Drug-Induced Changes in Epigenetic Silencing in Living Cells. DNA Cell Biol. (2012) Feb 7. [NCBI PubMed Entry]

Beltran, A and Blancafort, P. Reactivation of Maspin in Non-Small Cell Lung Carcinoma cells (NSCLC) by Artificial Transcription Factors (ATFs). Epigenetics. 2011 Feb 20;6(2). [NCBI PubMed Entry]

Beltran, A. S., Russo, A, Lara, H, Fan, C, Lizardi, P. M, Blancafort, P. Suppression of breast tumor growth and metastasis by an engineered transcription factor. PLoS One. 2011. 6: 9 e24595 [NCBI PubMed Entry]

Beltran AS, Rivenbark AG, Richardson BT, Yuan X, Quian H, Hunt JP, Zimmerman E, Graves LM, Blancafort P. Generation of tumor-initiating cells by exogenous delivery of OCT4 transcription factor. Breast Cancer Res. 2011 Sep 27;13(5):R94 [NCBI PubMed Entry]

Beltran, A., Blancafort, P. Remodeling genomes with Artificial Transcription Factors and chromatin remodeling drugs. Zinc Finger Protocols. Humana Press. Methods Mol Biol. 2010;649: 163-82. [NCBI PubMed Entry]

Beltran, A., Sun, X., Lizardi,PM, Blancafort, P. Reprogramming epigenetic silencing: Artificial Transcription Factors synergize with chromatin remodeling drugs to re-activate the tumor suppressor mammary serine protease inhibitor maspin. Mol Cancer Ther. 2008;7:1080-90. [NCBI PubMed Entry]

Blancafort P, Beltran AS. Rational Design, Selection and Specificity of Artificial Transcription Factors (ATFs): The Influence of Chromatin in Target Gene Regulation. Comb Chem High Throughput Screen. (2008);11:146-58. [NCBI PubMed Entry]

Blancafort, P., Tschan, M.P., Edrmann, D., Barbas III, C.F. Modulation of drug resistance by artificial transcription factors. Mol Cancer Ther. (2008); 7:688-97. [NCBI PubMed Entry]

Beltran, A., Parikh, S., Liu, Y., Cuevas, BD, Johnson GL, Fustcher, BW and Blancafort, P. Reactivation of a dormant tumor suppressor by designed transcription factors. Oncogene. (2007);26:2791-8. [NCBI PubMed Entry]

Beltran, A., Liu, Y., Parikh, S., Brenda, T., and Blancafort, P. Interrogating genomes with combinatorial transcription factor libraries: asking zinc finger questions. Assay Drug Dev Technol. (2006); 4:317-331 [NCBI PubMed Entry]

Dreier, B., Fuller, R.P, Segal, D.J., Lund, C., Blancafort, P., Huber, A., Koksch, B., and Barbas, C.F.III. Development of zinc finger domains for recognition of the 5’-CNN-3’ family DNA sequences and their use in the construction of artificial transcription factors. J. Biol. Chem. (2005); 280: 35588-97. [NCBI PubMed Entry]

Blancafort, P., Chen, E., Gonzalez, B., Bergquist, S., Zijlstra, A., Guthy, D., Brachat, A., Brakenhoff, R., Quigley, J., Edrmann, D., and Barbas C.F.III. Genetic reprogramming of tumor cells by zinc finger transcription factors. Proc. Natl. Acad. Sci. (2005); 102:11716-21. [NCBI PubMed Entry]

Magnenat, L., Blancafort, P. and Barbas III, C.F. In vivo library selection and designed affinity manuration of polydactyl zinc finger transcription factors for ICAM–1 gene regulation. J. Mol. Biol. (2004); 341:635-49. [NCBI PubMed Entry]

Blancafort, P, Segal, D.J., and Barbas III, C.F. Designing transcription factor architectures for drug design. Mol Pharmacol. (2004); 66:1361-71. [NCBI PubMed Entry]

Lund, C.V, Blancafort, P., Popkov, M. and Barbas III, C.F. Promoter-targeted Phage Display Selections with Preassembled Synthetic Zinc Finger Libraries for Endogenous Gene Regulation. J.Mol. Biol. (2004); 340:599-613. [NCBI PubMed Entry]

Blancafort,P., Magnenat, L. and Barbas III, C.F. Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol. (2003);21:269-74. [NCBI PubMed Entry]

Segal, D.J., Beerli R.R, Blancafort, P., Dreider, B., Effertz, K., Huber, A., Koksch, B., Magnenat, L., Valente, D., and Barbas III., C.F. (2003). Evaluation of a modular strategy for the construction of novel polydactyl zinc finger DNA-binding proteins. Biochemistry. 2003; 42:2137-48. [NCBI PubMed Entry]

Blancafort, P., Klinck, R., Steinberg, S., Scott, J.K. and Cedergren, R. The recognition of a non-canonical base pair by a zinc finger protein. Chem Biol. (1999); 6:585-97. [NCBI PubMed Entry]

Blancafort, P., Ferbeyre, G., Sariol, C., and Cedergren, R. Pol I-driven integrative expression vectors for yeast. Journal of Biotechnology (1997);56:41-7 [NCBI PubMed Entry]

Ferbeyre, G., Bratty, J., Blancafort, P., and Cedergren, R. (1995). Yeast as a model for hammerhead ribozyme action. Yeast, 11:15-48A.